TD Cowen Maintains Buy on TransMedics Group, Lowers Price Target to $120

Benzinga Newsdesk www.benzinga.com Neutral 42.5%

Neg 0% Neu 42.5% Pos 0%

TD Cowen analyst Joshua Jennings maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $190 to $120.